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Conclusion.— Percutaneous stent placement for management of
native or recurrent aortic coarctation is an efﬁcient and safe
alternative to surgery, and is associated with a long term reduction
in blood pressure and LV hypertrophy.
http://dx.doi.org/10.1016/j.acvd.2013.06.033
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Background.— Percutaneous closure of huge and tubular (type C)
patent ductus arteriosus remain challenging or unsuccessful in small
infants.
Aim.— To evaluate the usefulness and safety of Amplatzer vascu-
lar plug II and IV for percutaneous closure of very large ductus
arteriosus under 6 kg.
Methods.— Single-center retrospective study including all con-
secutive unselected patients (≤ 6 kg, large symptomatic ductus
arteriosus) referred to our institution over a 4 years period for per-
cutaneous closure and treated with plug II or IV. No patient was
excluded and there was no failure or surgery within the weight limit
to consider percutaneous closure (> 2.5 kg).
Results.— Seven patients were successfully treated using vascu-
lar plug II and IV without any residual shunt. Six plug II were
implanted (mean patients weight 4.3± 0.8 kg, mean ductus diame-
ter 6± 1.8mm, mean device size 8.6mm (6—14), ﬂuoroscopy time
14.8± 6.3min, occlusion rate 100%, mean follow-up 6± 2months)
including huge type C (5) and one type E (1) ductus. Mean pulmonary
artery pressure dropped from 25± 7 (17—38) mm of Hg to normal
value in all cases and there was no aortic protrusion or embolization.
One patient experienced severe but reversible pulmonary hyperten-
sion crisis in the catheter lab requiring blood transfusion. A 6mm
Amplatzer vascular plug IV was also implanted in a 4.2 kg patient
(4.8mm type D ductus, ﬂuoroscopy 10min, uneventful 8months
follow-up).
Conclusion.— Percutaneous closure of very large ductus arteriosus
is safe and effective under 6 kg. In our experience, the vascular plug
II proﬁle allows with acceptable risk to extend indication to infants
below 4 kg with huge tubular forms. This might contribute to reduce
surgical indications and in hospital morbidities and to improve cost
effectiveness. We believe that plug II could also be proposed in
the near future for closure of conical shape (type A) with similar
results.
http://dx.doi.org/10.1016/j.acvd.2013.06.034
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Background.— Cardiac catheterization procedures are being
increasingly performed in children with congenital heart disease for
diagnostic and treatment purposes. Given children’s greater sensi-
tivity to radiation and the longer life span during which radiation
health effects can develop, the ALARA principle (irradiation As Low
As Reasonably Achievable) is of peculiar importance. We report the
radiation doses and related factors for children who underwent car-
diac catheterization procedure in Toulouse children Hospital from
January to April 2013.
Methods.— We prospectively included 60 children (mean age 4 years
old, weight 2.350—59 kgs) undergoing a therapeutic (n = 55, 91.7%)
or diagnostic (n = 5, 8.3%) cardiac catheterization procedures. We
investigated the relationship between dose area product (DAP), ﬂu-
oroscopic time (FT), pulsed ﬂuoroscopic DAP, image acquisition DAP,
age, morphological parameters and double products combining FT
and weight or size or body mass index (BMI) or body surface area
(BSA). BSA was calculated according to the Mosteller formula.
Results.— The mean DAP was 20,697± 29,342mgycm2. The
mean total ﬂuoroscopic time was 24.6± 19.7min. DAP was not
signiﬁcantly different between diagnostic and therapeutic catheter-
ization (P = 0.98). Although image acquisition DAP accounted for
only 4.4± 2.4% of FT, it represented 42.5± 19.6% of DAP. DAP
was moderately although signiﬁcantly correlated with FT (r = 0.73,
P < 0.0001), BSA (r = 0.44, P = 0.0011), age (r = 0.37, P = 0.0082),
weight (r = 0.43, P = 0.002) and size (r = 0.38, P = 0.0052). DAP was
strongly associated with FT×Weight (r = 0.92, P < 0.0001), FT×BSA
(r = 0.93, P < 0.0001) and FT× Size (r = 0.91, P < 0.0001). Linear
regression analysis model involving FT×BSA to predict DAP was sig-
niﬁcant (P < 0.0001). Approximately 90% of the variance of DSA was
accounted for by this model.
Conclusion.— FT and morphological features (BSA, weight, size)
are the key parameters associated with DAP. Peculiar attention to
reduce FT and avoid unnecessary image acquisition may decrease
irradiation during catheterization in children with congenital heart
disease.
http://dx.doi.org/10.1016/j.acvd.2013.06.035
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Background.— DNA banks containing samples of patients with con-
genital heart disease are being developed at international level.
The accurate anatomic description of the cardiac phenotype of such
samples is a key feature for their success.
Objective and methods.— To precisely describe the cardiac pheno-
type of the available samples of the ‘‘CARREG’’ DNA bank, started in
April 2009 in our institution, based on the recently published clin-
ical and anatomic classiﬁcation (ACC-CHD) and the International
Pediatric and Congenital Cardiac Code (IPCCC). Samples collected
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from 01.04.2009 to 31.10.2011 were classiﬁed retrospectively based
on medical records including surgical and imaging reports. Samples
collected from 01.11.2011 onwards were classiﬁed prospectively.
Results.— Since creation of the DNA bank, 2364 blood samples have
been collected after informed consent of patients and their legal
representatives. They are stored in a dedicated space of the insti-
tution’s general DNA bank. Among them, there are 1299 patients’
samples and 1065 samples belonging to parents or relatives. Four
hundred and sixteen triple samples (patient and both parents) have
been obtained. One hundred and ﬁfty-eight samples come from
families with at least two members affected by congenital heart
disease. Eighty-eight samples belong to patients without congeni-
tal cardiac defects but with other severe cardiac pathologies. Six
hundred and ﬁfty-two patient samples (50%) were coded retrospec-
tively. Based on the ACC-CHD classiﬁcation, ‘‘CARREG’’ contains 658
samples (51%) belonging to the group 8 (anomalies of the outﬂow
tract). One hundred and ﬁfty-two samples (12%) were attributed
to group 4 (anomalies of the atrioventricular valve). The remaining
samples were classiﬁed in group 1: 41 (3%), group 2: 22 (2%), group
3: 85 (7), group 5: 31 (2%), group 6: 62 (5%), group 7: 55 (4%), group
9: 95 (7%) and group 10: 9 (1%).
Perspectives.— To make international comparison and data
exchange easier, cardiac phenotyping in ‘‘CARREG’’ relies on
IPCCC and the newly developed ACC-CHD. First cooperations with
national and international research partner are in progress. The
development of a limited access website as communicative plat-
form for researches will be one of the major goals in the near
future.
http://dx.doi.org/10.1016/j.acvd.2013.06.036
